Research programme: mTORC1 modulators - Navitor Pharmaceuticals

Drug Profile

Research programme: mTORC1 modulators - Navitor Pharmaceuticals

Alternative Names: NV-5318

Latest Information Update: 22 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Navitor Pharmaceuticals; X-Chem
  • Developer Navitor Pharmaceuticals; Yale University
  • Class Small molecules
  • Mechanism of Action MTORC1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Depressive disorders
  • Research Autoimmune disorders; Cancer; Metabolic disorders; Musculoskeletal disorders; Neurodegenerative disorders

Most Recent Events

  • 22 Nov 2017 Preclinical data for Depressive disorders released by Navitor Pharmaceuticals
  • 15 Nov 2017 Navitor plans to advance NV 5318 into clinical development in the first half of 2018
  • 01 Jun 2017 Preclinical trials in Depressive disorders (Treatment-resistant) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top